ARCHIVES

DCT Board Approves Drug Development Recompetition

This article is from The Cancer Letter archive.

Vol. 16 No. 46 | November 30, 1990

Download PDF Visit The Full Archive

Related Articles

Phase III Trial of Imbruvica Halted, Following Increases in Progression-Free Survival

January 31, 2014

Zerhouni Appoints Two Institute Directors

September 13, 2002

In Brief: Bristol To Drop Angiostatin; Protein Fails To Meet Criteria For Development, Firm Says

February 12, 1999

In Brief: Cancer Control Funds For Clinical Trials Intended To Upgrade Quality of Care: Terry

January 16, 1981

Gleevec Decreases Recurrence Of Gastrointestinal Tumor

April 27, 2007

Women Less Likely Than Men To Win Research Funding, Study Finds.

January 15, 2010